Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses the results of a study looking at pembrolizumab (Keytruda) in patients with triple-negative breast cancer (TNBC).
Sara A. Hurvitz, MD
Sara Hurvitz, MD, is a medical oncologist, clinical research leader, and senior vice president of the clinical research division at Fred Hutchinson Cancer Center in Seattle, WA. She is also the head of the division of hematology and oncology at the University of Washington Department of Medicine.
Articles by Sara A. Hurvitz, MD
Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses future treatment options for triple-negative breast cancer (TNBC).
Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses patient outcomes associated with PIK3CA mutations.